We evaluated the inhibition profiles obtained with ex vivo exposure of melanoma tumour lysates to a V600EBRAF inhibitor (dabrafenib) with two purposes: (1) to gain a more comprehensive insight into the pathways that have an impact on the response to BRAF inhibitors, and (2) to distinguish responders from non-responders based on relative signal intensities (log fold change inhibited/non-inhibited) to overcome the differences in basal kinase activity between the patients. Here, BRAF is linked to melanoma.